Enantiomeric characterization and structure elucidation of Otamixaban

Otamixaban is a potent (Ki=0.5 nM) fXa inhibitor currently in late-stage clinical development at Sanofi for the management of acute coronary syndrome. Being unproductive in obtaining a suitable crystal of Otamixaban, the required enantiomeric characterization has been accomplished using vibrational...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jian, Yang, Jiping, Heyse, Winfried, Schweitzer, Harald, Nagel, Norbert, Andert, Doris, Zhu, Chengyue, Morrison, Vincent, Nemeth, Gregory A., Chen, Teng-Man, Zhao, Zhicheng, Ayers, Timothy A., Choi, Yong-Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Xi'an Jiaotong University 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761123/
https://www.ncbi.nlm.nih.gov/pubmed/29403883
http://dx.doi.org/10.1016/j.jpha.2013.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761123/
https://www.ncbi.nlm.nih.gov/pubmed/29403883
http://dx.doi.org/10.1016/j.jpha.2013.10.001

Ejemplares similares